Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh (DiabCare Asia)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk A/S
ClinicalTrials.gov Identifier:
NCT01877200
First received: June 11, 2013
Last updated: October 22, 2013
Last verified: October 2013

June 11, 2013
October 22, 2013
June 2013
September 2013   (final data collection date for primary outcome measure)
Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7% [ Time Frame: Evaluated at the first visit (only one study visit) ] [ Designated as safety issue: No ]
Proportion of patients having HbA1c ((Glycosylated Haemoglobin) as measured during survey) less than 7% [ Time Frame: 1 day (only one study visit) ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01877200 on ClinicalTrials.gov Archive Site
  • Mean Fasting Plasma Glucose (FPG) of patients [ Time Frame: Evaluated at the first visit (only one study visit) ] [ Designated as safety issue: No ]
  • Mean Postprandial Plasma Glucose (PPG) of patients [ Time Frame: Evaluated at the first visit (only one study visit) ] [ Designated as safety issue: No ]
  • Mean HbA1c of patients [ Time Frame: Evaluated at the first visit (only one study visit) ] [ Designated as safety issue: No ]
  • Proportion of patients having dyslipidemia and hypertension [ Time Frame: Evaluated at the first visit (only one study visit) ] [ Designated as safety issue: No ]
  • Proportion of patients having cardiovascular complications [ Time Frame: Evaluated at the first visit (only one study visit) ] [ Designated as safety issue: No ]
  • Proportion of patients having peripheral vascular disease [ Time Frame: Evaluated at the first visit (only one study visit) ] [ Designated as safety issue: No ]
  • Proportion of patients having diabetic nephropathy [ Time Frame: Evaluated at the first visit (only one study visit) ] [ Designated as safety issue: No ]
  • Proportion of patients having diabetic eye complications [ Time Frame: Evaluated at the first visit (only one study visit) ] [ Designated as safety issue: No ]
  • Mean Fasting Plasma Glucose (FPG) of patients [ Time Frame: 1 day (only one study visit) ] [ Designated as safety issue: No ]
  • Mean Postprandial Plasma Glucose (PPG) of patients [ Time Frame: 1 day (only one study visit) ] [ Designated as safety issue: No ]
  • Mean HbA1c of patients [ Time Frame: 1 day (only one study visit) ] [ Designated as safety issue: No ]
  • Proportion of patients having dyslipidemia and hypertension [ Time Frame: 1 day (only one study visit) ] [ Designated as safety issue: No ]
  • Proportion of patients having cardiovascular complications [ Time Frame: 1 day (only one study visit) ] [ Designated as safety issue: No ]
  • Proportion of patients having peripheral vascular disease [ Time Frame: 1 day (only one study visit) ] [ Designated as safety issue: No ]
  • Proportion of patients having diabetic nephropathy [ Time Frame: 1 day (only one study visit) ] [ Designated as safety issue: No ]
  • Proportion of patients having diabetic eye complications [ Time Frame: 1 day (only one study visit) ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh
A Cross-Sectional Survey to Evaluate Diabetes Management, Control, Complications, Psychosocial Aspects of Patients With Type 2 Diabetes in Bangladesh

This study is conducted in Asia. The aim of this non-interventional study is to evaluate the the current status of diabetes management, control, and complications in diabetic subjects with type 2 diabetes in Bangladesh.

Not Provided
Observational
Observational Model: Ecologic or Community
Time Perspective: Cross-Sectional
Not Provided
Not Provided
Non-Probability Sample

People treated for at least a year are eligible for the study. The selection of the patients will be done randomly by the individual physician involved in the study.

  • Diabetes
  • Diabetes Mellitus, Type 2
Other: No treatment given
Patients will fill out a questionnaire by interview.
Subjects with diabetes (type 2)
Intervention: Other: No treatment given
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2092
September 2013
September 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • People with type 2 diabetes mellitus (DM) who are being treated, with any of the non-pharmacological or pharmacological options, at a particular centre for at least 1 year and who have visited the centre within the last 3-6 months
  • Patients willing to sign informed consent form

Exclusion Criteria:

  • Previous participation in this study
  • Unable to comply with protocol requirements
  • Confirmed or suspected pregnancy
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Bangladesh
 
NCT01877200
INS-4071, U1111-1138-9347
No
Novo Nordisk A/S
Novo Nordisk A/S
Not Provided
Study Director: Global Clinical Registry (GCR, 1452) Novo Nordisk A/S
Novo Nordisk A/S
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP